| Geld/Brief | 23,03 $ / 25,57 $ |
| Spread | +11,03% |
| Schluss Vortag | 23,08 $ |
| Gehandelte Stücke | 29.758 |
| Tagesvolumen Vortag | 137.901,1 $ |
| Tagestief 22,40 $ Tageshoch 23,55 $ | |
| 52W-Tief 5,90 $ 52W-Hoch 24,82 $ | |
| Jahrestief 16,92 $ Jahreshoch 24,00 $ | |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| NYSE | 22,64 $ | -0,68% | 22,795 $ | 03.02.26 | |
| Nasdaq | 23,50 $ | +1,82% | 23,08 $ | 21:59 | |
| AMEX | 21,83 $ | 0 % | 21,83 $ | 29.12.25 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 03.02.26 | 23,28 | 157 T |
| 02.02.26 | 22,10 | 230 T |
| 30.01.26 | 21,545 | 119 T |
| 29.01.26 | 21,94 | 78 T |
| 28.01.26 | 21,83 | 116 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 21,83 $ | +6,64% |
| 1 Monat | 21,55 $ | +8,03% |
| 6 Monate | 10,63 $ | +119,00% |
| 1 Jahr | 11,31 $ | +105,84% |
| 5 Jahre | - | - |
| Marktkapitalisierung | 38,39 Mio. € |
| Währung | EUR |
| Aktientyp | Stammaktie |
Zahlen für Q2/23
-SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023
-SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023
-Corporate prioritization efforts expected to provide cash runway extension into 2025
https://investors.surrozen.com/news-releases/news-release-details/surrozen-provides-second-quarter-2023-financial-results
Zahlen für Q1/23
- cash runway into the second half of 2024
- SZN-043 Phase 1a with safety data expected by the end of 2023
- SZN-1326 Phase 1a with safety data expected by the end of 2023
https://investors.surrozen.com/news-releases/news-release-details/surrozen-provides-first-quarter-2023-financial-results-and
Mit Cash für ca. 4 Quartalen könnten sich die beiden Katalysatoren in Q4 noch gut mitnehmen lassen.